UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

PTEN-deficient cancers depend on PIK3CB

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (35), p.13057-13062

2008

Volltextzugriff (PDF)

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (10), p.4286-4293

2009

Volltextzugriff (PDF)

Single-vector inducible lentiviral RNAi system for oncology target validation

Cell cycle (Georgetown, Tex.), 2009-02, Vol.8 (3), p.498-504

2009

Volltextzugriff (PDF)

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations

Clinical cancer research, 2017-09, Vol.23 (18), p.5547-5560

2017

Volltextzugriff (PDF)

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T‐cell lymphoma models: Defining molecular mechanisms of resistance

International journal of cancer, 2010-11, Vol.127 (9), p.2199-2208

2010

Volltextzugriff (PDF)

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (7), p.2643-2653

2011

Volltextzugriff (PDF)

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/β-catenin signaling

Proceedings of the National Academy of Sciences - PNAS, 2011-10, Vol.108 (41), p.17135-17140

2011

Volltextzugriff (PDF)

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

ACS medicinal chemistry letters, 2010-06, Vol.1 (3), p.130-134

2010

Volltextzugriff (PDF)

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

Haematologica (Roma), 2010-05, Vol.95 (5), p.794-803

2010

Volltextzugriff (PDF)

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

Proceedings of the National Academy of Sciences - PNAS, 2010-08, Vol.107 (35), p.15473-15478

2010

Volltextzugriff (PDF)

The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells

Cancer research (Chicago, Ill.), 2010-07, Vol.70 (13), p.5528-5538

2010

Volltextzugriff (PDF)

c-Jun N-Terminal Kinases Mediate Reactivation of Akt and Cardiomyocyte Survival After Hypoxic Injury In Vitro and In Vivo

Circulation research, 2006-01, Vol.98 (1), p.111-118

2006

Volltextzugriff (PDF)

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma

Science translational medicine, 2010-09, Vol.2 (51), p.51ra70

2010

Volltextzugriff (PDF)

Upconverting Phosphor Reporters in Immunochromatographic Assays

Analytical biochemistry, 2001-01, Vol.288 (2), p.176-187

2001

Volltextzugriff (PDF)

Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors

Journal of medicinal chemistry, 2011-07, Vol.54 (13), p.4752-4772

2011

Volltextzugriff (PDF)

VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia

Journal of medicinal chemistry, 2012-01, Vol.55 (2), p.725-734

2012

Volltextzugriff (PDF)

High Sensitivity Immunoassays Using Particulate Fluorescent Labels

Analytical biochemistry, 1999-08, Vol.272 (2), p.165-170

1999

Volltextzugriff (PDF)

The IMPDH Inhibitor VX-944 Demonstrates In Vivo Efficacy in an Aggressive Leukemia Model

Blood, 2004-11, Vol.104 (11), p.2530-2530

2004

Volltextzugriff (PDF)

Abstract 4835: LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4835-4835

2019

Volltextzugriff (PDF)

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3632-3632

2018

Volltextzugriff (PDF)

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B108-B108

2018

Volltextzugriff (PDF)

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A160-A160

2018

Volltextzugriff (PDF)

Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2730-2730

2018

Volltextzugriff (PDF)

Abstract LB-004: Mouse PDX Trial Suggests Combination Efficacy of Raf and EGFR Inhibition in Colorectal Cancer with BRaf or KRas mutation

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.LB-004-LB-004

2015

Volltextzugriff (PDF)

Isolation and characterization of a cDNA that encodes an agrin homolog in the marine ray

Molecular and cellular neuroscience, 1992-10, Vol.3 (5), p.406-417

1992

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)
Dissertationen
(1)

Sprache

Englisch
(36)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Animals
(18)
Life Sciences & Biomedicine
(17)
Humans
(14)
Mice
(14)
Cell Line, Tumor
(9)
Tumors
(9)
Biological And Medical Sciences
(8)
Mice, Nude
(6)
Cancer
(5)
Medical Sciences
(5)
Mutation
(5)
Oncology
(5)
Signal Transduction
(5)
Antineoplastic Agents
(4)
Antineoplastic Agents - Pharmacology
(4)
Female
(4)
Neoplasm Transplantation
(4)
Proteins
(4)
Transplantation, Heterologous
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PTEN-deficient cancers depend on PIK3CB

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

Single-vector inducible lentiviral RNAi system for oncology target validation

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T‐cell lymphoma models: Defining molecular mechanisms of resistance

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/β-catenin signaling

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells

c-Jun N-Terminal Kinases Mediate Reactivation of Akt and Cardiomyocyte Survival After Hypoxic Injury In Vitro and In Vivo

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma

Upconverting Phosphor Reporters in Immunochromatographic Assays

Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors

VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia

High Sensitivity Immunoassays Using Particulate Fluorescent Labels

The IMPDH Inhibitor VX-944 Demonstrates In Vivo Efficacy in an Aggressive Leukemia Model

Abstract 4835: LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054

Abstract LB-004: Mouse PDX Trial Suggests Combination Efficacy of Raf and EGFR Inhibition in Colorectal Cancer with BRaf or KRas mutation

Isolation and characterization of a cDNA that encodes an agrin homolog in the marine ray

Suchergebnisse filtern